Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
By
Jeremy Veenstra-VanderWeele
28 January 2020 | 5 min read
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
By
Jeremy Veenstra-VanderWeele
10 June 2014 | 8 min read
Explore more from The Transmitter
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
From friend to foe: How the brain updates feelings toward others
A specific hippocampus-to-amygdala pathway reassigns emotional valence to a known individual, whereas the hippocampus’s own representation of that individual’s identity remains stable.
By
Natalia Mesa
9 July 2026 | 5 min read
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
Mass-produced science is coming. What happens to scientists?
Artificial intelligence may soon enable researchers to generate high-quality science at a previously unimaginable speed. For science consumers—the public, medical patients, technology users—the likely effects will be positive. For scientists, the effects will be as disruptive as industrial mass production was for artisan manufacturers.
By
Kenneth Harris
9 July 2026 | 9 min read
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.
Neuropathologist not guilty of research misconduct, says university probe
The investigation determined that seven papers by corresponding author Adriano Aguzzi have “scientifically significant” errors, which Aguzzi attributes to his former students.
By
Dalmeet Singh Chawla
8 July 2026 | 5 min read